Sun Ming, Nie Feng-Qi, Zang Chongshuang, Wang Yunfei, Hou Jiakai, Wei Chenchen, Li Wei, He Xiang, Lu Kai-Hua
Department of Oncology, First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China; Department of Bioinformatics and Computational Biology, UT MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China.
Mol Ther. 2017 Mar 1;25(3):739-751. doi: 10.1016/j.ymthe.2016.12.018. Epub 2017 Jan 25.
Recently, the non-protein-coding functional elements in the human genome have been identified as key regulators in postgenomic biology, and a large number of pseudogenes as well as long non-coding RNAs (lncRNAs) have been found to be transcribed in multiple human cancers. However, only a small proportion of these pseudogenes has been functionally characterized. In this study, we screened for pseudogenes associated with human non-small-cell lung cancer (NSCLC) by comparative analysis of several independent datasets from the GEO. We identified a transcribed pseudogene named DUXAP8 that is upregulated in tumor tissues. Patients with higher DUXAP8 expression exhibited shorter survival, suggesting DUXAP8 as a new candidate prognostic marker for NSCLC patients. Knockdown of DUXAP8 impairs cell growth, migration, and invasion, and induces apoptosis both in vitro and in vivo. Mechanistically, DUXAP8 represses the tumor suppressors EGR1 and RHOB by recruiting histone demethylase LSD1 and histone methyltransferase EZH2, thereby promoting cell proliferation, migration, and invasion. These findings indicate that the pseudogene DUXAP8 may act as an oncogene in NSCLC by silencing EGR1 and RHOB transcription by binding with EZH2 and LSD1, which may offer a novel therapeutic target for this disease.
最近,人类基因组中的非蛋白质编码功能元件已被确定为后基因组生物学中的关键调节因子,并且已发现大量假基因以及长链非编码RNA(lncRNA)在多种人类癌症中被转录。然而,这些假基因中只有一小部分具有功能特征。在本研究中,我们通过对来自GEO的几个独立数据集进行比较分析,筛选了与人类非小细胞肺癌(NSCLC)相关的假基因。我们鉴定出一个名为DUXAP8的转录假基因,其在肿瘤组织中上调。DUXAP8表达较高的患者生存期较短,这表明DUXAP8是NSCLC患者的一个新的候选预后标志物。敲低DUXAP8会损害细胞生长、迁移和侵袭,并在体外和体内诱导细胞凋亡。从机制上讲,DUXAP8通过招募组蛋白去甲基化酶LSD1和组蛋白甲基转移酶EZH2来抑制肿瘤抑制因子EGR1和RHOB,从而促进细胞增殖、迁移和侵袭。这些发现表明,假基因DUXAP8可能通过与EZH2和LSD1结合使EGR1和RHOB转录沉默,从而在NSCLC中充当癌基因,这可能为该疾病提供一个新的治疗靶点。